The DOI matches its Crossref record.
Efficacy and Safety of Treprostinil: An Epoprostenol Analog for Primary Pulmonary Hypertension
Abstract
Intravenous epoprostenol is currently FDA approved for management of primary pulmonary hypertension, but it requires intravenous infusion and is associated with adverse effects. The objective of this study was to evaluate the effects of an epoprostenol analog, treprostinil, for management of pulmonary hypertension. Ten tertiary care academic institutions with pulmonary hypertension programs participated in these pilot trials. In the first trial, intravenous epoprostenol and intravenous treprostinil were compared. In the second trial, intravenous treprostinil and subcutaneous treprostinil were compared. In the third trial, subcutaneous treprostinil was compared with placebo infusion during an 8-week period. Intravenous epoprostenol and intravenous treprostinil resulted in a similar reduction in pulmonary vascular resistance acutely (22% and 20%, respectively). Intravenous treprostinil and subcutaneous treprostinil also demonstrated comparable short-term decrease in pulmonary vascular resistance (23% and 28%, respectively). The placebo-controlled 8-week trial demonstrated a mean improvement of 37 +/- 17 m as measured by the 6-minute walk distance in patients receiving treprostinil compared with a 6 +/- 28 m reduction in those receiving placebo. There were trends toward an improvement in cardiac index and pulmonary vascular resistance index in the treprostinil group. Subcutaneous treprostinil has favorable hemodynamic effects when given acutely and in the short term. Treprostinil can be given safely to an ambulatory patient with a novel subcutaneous delivery pump system.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Selexipag for the Treatment of Pulmonary Arterial Hypertension
Sitbon, O., Channick, R., Chin, K. M., Frey, A., Gaine, S., Galiè, N., Ghofrani, H.-A., Hoeper, M. M., Lang, I. M., Preiss, R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503184 · Cited by 1,060
Self-citationIn vitro microvessels for the study of angiogenesis and thrombosis
Zheng, Y., Chen, J., Craven, M., Choi, N. W., Totorica, S., Diaz-Santana, A., Kermani, P., Hempstead, B., Fischbach-Teschl, C., López, J. A., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1201240109 · Cited by 894
Medical Therapy For Pulmonary Arterial Hypertension
Badesch, D. B., Abman, S. H., Ahearn, G. S., Barst, R. J., McCrory, D. C., Simonneau, G., & McLaughlin, V. V. (2004) · Chest · doi:10.1378/chest.126.1_suppl.35s · Cited by 829
Self-citationPulmonary Arterial Hypertension
McLaughlin, V. V., & McGoon, M. D. (2006) · Circulation · doi:10.1161/circulationaha.104.503540 · Cited by 664
Self-citationUpdated Evidence-Based Treatment Algorithm in Pulmonary Arterial Hypertension
Barst, R. J., Gibbs, J. S. R., Ghofrani, H. A., Hoeper, M. M., McLaughlin, V. V., Rubin, L. J., Sitbon, O., Tapson, V. F., & Galiè, N. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.04.017 · Cited by 499
Self-citation
Metadata
- Authors
- McLaughlin, V. V., Gaine, S. P., Barst, R. J., Oudiz, R. J., Bourge, R. C., Frost, A., Robbins, I. M., Tapson, V. F., McGoon, M. D., Badesch, D. B., Sigman, J., Roscigno, R., Blackburn, S. D., Arneson, C., Rubin, L. J., & Rich, S.
- Venue
- Journal of Cardiovascular Pharmacology
- Published
- 2003-02
- Volume
- 41
- Issue
- 2
- Pages
- 293-299
- ISSN
- 0160-2446 (ISSN-L)
- OpenAlex
- W2008067043
- Cited by
- 232
- References
- 0
- FWCI
- 14.61
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy and Safety of Treprostinil: An Epoprostenol Analog for Primary Pulmonary Hypertension. https://app.cochat.ai/papers/10.1097/00005344-200302000-00019
- The paper
- McLaughlin, V. V., Gaine, S. P., Barst, R. J., Oudiz, R. J., Bourge, R. C., Frost, A., Robbins, I. M., Tapson, V. F., McGoon, M. D., Badesch, D. B., Sigman, J., Roscigno, R., Blackburn, S. D., Arneson, C., Rubin, L. J., & Rich, S. (2003). Efficacy and Safety of Treprostinil: An Epoprostenol Analog for Primary Pulmonary Hypertension. Journal of Cardiovascular Pharmacology. https://doi.org/10.1097/00005344-200302000-00019
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.